Search
Givosiran
go.drugbank.com/drugs/DB15066Approved[L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies
Flotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigationalFlotufolastat F-18 (18F-rhPSMA-7.3) is an 18F-labeled ligand that targets the prostate-specific membrane antigen (PSMA). In patients with recurrent prostate cancer that require localized treatment, the use of 18F-labeled ligands for posi...
Ginsenoside Rb1
go.drugbank.com/drugs/DB06749ExperimentalNutraceuticalGinsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy.
5'-Guanosine-Diphosphate-Monothiophosphate
go.drugbank.com/drugs/DB01864ExperimentalA stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific
Nelistotug
go.drugbank.com/drugs/DB19334InvestigationalNelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous
ZD4407
go.drugbank.com/drugs/DB06539ExperimentalThe drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
AdimrSC-2f
go.drugbank.com/drugs/DB16436InvestigationalThe AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].
Prolectin-M
go.drugbank.com/drugs/DB16521InvestigationalProlectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin.
Cetrelimab
go.drugbank.com/drugs/DB15421Investigationalinvestigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as
Belnacasan
go.drugbank.com/drugs/DB05507InvestigationalVX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.